Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from ArcticZymes Technologies ASA ( (DE:B4V) ) is now available.
ArcticZymes Technologies reported a decrease in revenue for the fourth quarter of 2024, with total revenues of NOK 26.4 million, reflecting a transition period as the company focuses on long-term growth initiatives. The company has made significant progress in its commercial transformation, with a notable 31% increase in biomanufacturing customer numbers and the introduction of new products like the SAN HQ GMP neo and SAN HQ ELISA SensoPlus, aimed at enhancing their product offerings and market positioning.
More about ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company specializing in the development, manufacturing, and commercialization of recombinant enzymes for molecular research, In Vitro Diagnostics, and biomanufacturing. The company is listed on the Oslo Stock Exchange and is headquartered in Tromsø, Norway.
YTD Price Performance: 12.90%
Average Trading Volume: 1,948
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €62.75M
For detailed information about B4V stock, go to TipRanks’ Stock Analysis page.